// App-Quantinova.ai

P2-10-04 : Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multi-center trial

Researchers

Presenter

  • HD Bear

Principal Investigators

  • W Wan

  • A Robidoux

  • P Rubin

  • S Limentani

  • RL White, Jr

  • J Granfortuna

  • JO Hopkins

  • D Oldham

  • A Rodriguez

  • AP Sing

Medical Centers

  • Virginia Commonwealth University Medical Center, Richmond, VA

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Forsyth Regional Cancer Center, Winston-Salem, NC

  • Lynchburg Hematology Oncology Clinic, Lynchburg, VA

  • Carolinas Medical Center, Charlotte, NC

  • Houston Methodist Hospital, Houston, TX

  • Cone Health Cancer Center, Greensboro, NC

Locations

  • United States

  • Canada

Companies

  • Genomic Health, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved